Treatment of Inguinal Lymph Node Metastases in Patients with Rectal Adenocarcinoma
Background Inguinal lymph node metastases (ILNM) from rectal adenocarcinoma are rare and staged as systemic disease. This study aimed to provide insight into the treatment and prognosis of ILNM from rectal adenocarcinoma.
Methods All patients with a diagnosis of synchronous or metachronous ILNM from rectal adenocarcinoma between January 2005 and March 2017 were retrospectively reviewed.
Results The study identified 27 patients with ILNM (15 with synchronous and 12 with metachronous disease). After discussion by a multidisciplinary tumor board, 19 patients were treated with curative intent, 17 of whom underwent inguinal lymph node dissection. Of the 17 patients, 12 had locally advanced rectal cancer (LARC) with isolated ILNM, 3 had LARC and metastases elsewhere, and 2 had locally recurrent rectal cancer (LRRC). The median overall survival (OS) for all the patients treated with curative intent was 27 months [95% confidence interval (CI) 11.6–42.4 months], with a 5-year OS rate of 34%. The median OS for the patients with LARC and isolated ILNM (n = 12) was 74 months (95% CI 18.0–130.0 months), with a 5-year OS rate of 52%. All the patients with metastases elsewhere (n = 3) or LRRC (n = 2) experienced recurrent systemic disease. Eight patients were treated with palliative intent. The median OS for this group was 13 months (95% CI 1.9–24.1 months), with a 3-year OS rate of 0%.
Conclusion Clinicians should not consider ILNM as an incurable systemic disease. Patients with primary rectal cancer and solitary ILNM who were eligible for curative surgical treatment had a 5-year survival rate of 52%. The prognosis for patients with additional systemic metastases or LRRC is worse, and the benefit of surgery is unclear.
Locally advanced rectal cancer is associated with pelvic lymph node metastases inside and sometimes outside the mesorectum. Besides these locoregional lymph node metastases, inguinal lymph node metastases (ILNM) may occur, particularly in lower rectal cancer, due to the lymphatic drainage by inguinal lymph nodes.1 These ILNMs are relatively rare, and the number of patients described in the literature is low.2–7
The American Joint Committee on Cancer (AJCC) Cancer Staging Manual considers ILNM from rectal cancer as a systemic disease.8 Whether ILNM should be treated with palliative or curative intent is unclear.9–11 Obviously, patients with ILNM have a worse prognosis than patients without ILNM, but even patients with lung or liver metastases are not always restrained from curative treatment.12 The evidence in the literature whether patients with ILNM from rectal adenocarcinoma can possibly be cured is scarce, and few studies have described treatment for ILNM of rectal cancer.2,4–6
At our hospital, ILNM has been treated by inguinal lymph node dissection (ILND), with and without neoadjuvant chemotherapy, in case there were no other metastases or when limited metastases were present elsewhere. This report presents the results for patients treated with both curative and palliative intent for ILNM from rectal cancer.
|Persistent URL||dx.doi.org/10.1245/s10434-019-07191-4, hdl.handle.net/1765/116260|
|Journal||Annals of Surgical Oncology|
Hagemans, J.A.W., Rothbarth, Ph.H, van Bogerijen, G.H.W., van Meerten, E, Nuyttens, J., Verhoef, C, & Burger, J.W.A. (2019). Treatment of Inguinal Lymph Node Metastases in Patients with Rectal Adenocarcinoma. Annals of Surgical Oncology, 26(4), 1134–1141. doi:10.1245/s10434-019-07191-4